KPV vs Mazdutide (IBI362)
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of KPV and Mazdutide (IBI362) (also searched as Mazdutide (IBI362) vs KPV) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
KPV centers on healing, while Mazdutide (IBI362) leans toward metabolic. On indexed research, KPV is ahead (KPV: 6 studies, Human evidence; Mazdutide (IBI362): 1, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •KPV is strongest for healing; Mazdutide (IBI362) for metabolic.
- •Evidence: KPV Human evidence (6 studies) vs Mazdutide (IBI362) Human evidence (1).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Anti-Inflammatory Tripeptide | Alpha-MSH Fragment
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
KPV vs Mazdutide (IBI362): side-by-side
| Metric | KPV | Mazdutide (IBI362) |
|---|---|---|
| Class | Immune | Weight Loss |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 6 | 1 |
| Research level | Emerging | Extensively Studied |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 4.0▲ | 0.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 5.0▲ |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 4.0▲ | 0.0 |
| Skin & aesthetics | 2.0▲ | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | KPV | Mazdutide (IBI362) |
|---|---|---|
| Mechanism | — | GLP-1 / glucagon dual receptor agonist |
| Route | — | Subcutaneous injection |
| Duration of action | — | Weekly dosing (investigational) |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is KPV?
### KPV Summary KPV is a tripeptide composed of lysine, proline, and valine, which has garnered interest in research for its potential roles in modulating immune responses and promoting wound healing. Its implications in various therapeutic contexts, particularly in inflammatory conditions, are currently being explored.
Full KPV profile, mechanism & studies →What is Mazdutide (IBI362)?
Mazdutide (IBI362) is an investigational dual GLP-1/glucagon receptor agonist studied for weight loss and type 2 diabetes, combining appetite suppression with increased energy expenditure.
Full Mazdutide (IBI362) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | KPV | 4.0/5 effect signal |
| Metabolic | Mazdutide (IBI362) | 5.0/5 effect signal |
| Inflammation | KPV | 4.0/5 effect signal |
| Skin | KPV | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack KPV and Mazdutide (IBI362)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
KPV vs Mazdutide (IBI362): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
KPV has 6 approved studies indexed (Human evidence), and Mazdutide (IBI362) has 1 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is KPV or Mazdutide (IBI362) better?
It depends on your goal. KPV is strongest for healing; Mazdutide (IBI362) for metabolic. KPV has more indexed studies (6). See the goal-by-goal breakdown above.
Is KPV or Mazdutide (IBI362) better for weight loss?
Mazdutide (IBI362) shows the stronger metabolic & appetite profile (5.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Which has more research, KPV or Mazdutide (IBI362)?
KPV has 6 approved studies indexed (Human evidence); Mazdutide (IBI362) has 1 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack KPV and Mazdutide (IBI362)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of KPV vs Mazdutide (IBI362)?
KPV: no community-reported effects logged yet. Mazdutide (IBI362): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is KPV or Mazdutide (IBI362) FDA-approved?
KPV is a research-use compound and is not FDA-approved. Mazdutide (IBI362) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Mazdutide (IBI362) better than KPV?
For metabolic, Mazdutide (IBI362) has the edge; for healing, KPV does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
KPV and Mazdutide (IBI362) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.